Moreover, Curc-mPEG454 reversed HFD-induced hepatic steatosis and hypertriglyceridemia by modulating the hepatic CREB/PPARγ/cluster of differentiation 36 (CD36) pathway through the activation of CREB phosphorylation and inhibition of PPARγ and CD36 expression (Table 2) [98]. Here, PPARG is linked to fatty liver disease.